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Head and neck squamous cell carcinomas (HNSCC) are associated with
poor morbidity and mortality. Current treatment strategies are highly toxic
and do not benefit over 50% of patients. There is therefore a crucial need
for predictive and/or prognostic biomarkers to allow treatment stratifica-
tion for individual patients. One class of biomarkers that has recently
gained importance are microRNA (miRNA). MiRNA are small, noncod-
ing molecules which regulate gene expression post-transcriptionally. We
performed miRNA expression profiling of a cohort of head and neck
tumours with known clinical outcomes. The results showed miR-9 to be
significantly downregulated in patients with poor treatment outcome, indi-
cating its role as a potential biomarker in HNSCC. Overexpression of
miR-9 in HNSCC cell lines significantly decreased cellular proliferation
and inhibited colony formation in soft agar. Conversely, miR-9 knock-
down significantly increased both these features. Importantly, endogenous
CXCR4 expression levels, a known target of miR-9, inversely correlated
with miR-9 expression in a panel of HNSCC cell lines tested. Induced
overexpression of CXCR4 in low expressing cells increased proliferation,
colony formation and cell cycle progression. Moreover, CXCR4-specific
ligand, CXCL12, enhanced cellular proliferation, migration, colony forma-
tion and invasion in CXCR4-overexpressing and similarly in miR-9 knock-
down cells. CXCR4-specific inhibitor plerixafor abrogated the oncogenic
phenotype of CXCR4 overexpression as well as miR-9 knockdown. Our
data demonstrate a clear role for miR-9 as a tumour suppressor micro-
RNA in HNSCC, and its role seems to be mediated through CXCR4
suppression. MiR-9 knockdown, similar to CXCR4 overexpression, signifi-
cantly promoted aggressive HNSCC tumour cell characteristics. Our
results suggest CXCR4-specific inhibitor plerixafor as a potential therapeu-
tic agent, and miR-9 as a possible predictive biomarker of treatment
response in HNSCC.
Abbreviations
BD, Becton Dickinson Bioscience; G-CSF, granulocyte colony-stimulating factor; HNSCC, head and neck squamous cell carcinoma;
HSCs, haematopoietic stem cells; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Polyhema,
poly(2-hydroxyethylmethacrylate); SDF-1, stromal cell-derived factor 1.
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1. Introduction
Head and neck squamous cell carcinoma (HNSCC) is
the sixth most common cancer in the world with
approximately 650 000 new cases diagnosed each year
(Ferlay et al., 2010; Li et al., 2011; Raulf et al., 2014).
HNSCC are a group of heterogeneous tumours of the
oral cavity, oropharynx, larynx or hypopharynx that
usually present with locally advanced disease (Suh
et al., 2014). Several risk factors have been correlated
with HNSCC including tobacco, alcohol, genetic
susceptibility and viral infection (Ragin et al., 2007).
Typical treatment consists of surgery and radiother-
apy; however, patients generally develop resistance, as
a result, 5-year survival rates of HNSCC patients are
around 40–50% (Mehanna and Ang, 2012). Therefore,
predictive biomarkers and targeted therapies are
required to enable individualisation of treatment and
improve outcomes.
MicroRNA (miRNA) are small (20–22nt), tissue-
specific, noncoding RNA molecules that have an
important post-transcriptional regulatory role in gene
expression. Genomewide miRNA profiling studies per-
formed on various cancer types such as breast (Iorio
et al., 2005), glioblastoma (Chan et al., 2005), hepato-
cellular carcinoma (Murakami et al., 2006) and lung
(Yanaihara et al., 2006) amongst others (reviewed
Calin and Croce, 2006) showed that miRNA profiles
in cancers can be used to differentiate between disease
subtypes and predict patient survival and treatment
response (Lu et al., 2005). MiRNA expression in can-
cer was globally downregulated compared to normal
tissues and could be used to discriminate between dif-
ferent developmental lineage and differentiation status.
Expression profiling in prostate cancer has shown that
a panel of nine miRNA could discriminate between
neoplastic and normal tissue (Carlsson et al., 2011). In
cervical cancer-specific miRNA expression profiles
were predictive of stage (downregulation of seven
miRNA), metastasis (six miRNA) and prognosis (two
miRNA) (Huang et al., 2012). Moreover, miRNA
expression profiling performed in lung cancer showed
that specific miRNA signatures were able to discrimi-
nate between lung cancer and normal lung tissues and
were also able to differentiate between tumours with
different prognosis (Yanaihara et al., 2006). MiRNA
have potential diagnostic and prognostic roles as
biomarkers in a variety of cancers including HNSCC
(Hui et al., 2010, 2016; Summerer et al., 2015).
MiR-9 has emerged in recent years as an important
miRNA in various cancer types (Cekaite et al., 2012;
Liu et al., 2012; Song et al., 2014; Sun et al., 2009; Xu
et al., 2014). MiR-9 is encoded on chromosomes 1
(miRNA-9-1), 5 (miRNA-9-2) and 15 (miRNA-9-3) all
of which give rise to the same mature miRNA. All
three genomic loci have CpG islands, and hypermethy-
lation of miR-9 loci occurs in several different cancer
types including breast, lung, colon, melanoma, acute
lymphoblastic leukaemia and HNSCC (Bandres et al.,
2009; Hsu et al., 2009; Lujambio et al., 2008; Roman-
Gomez et al., 2009). MiR-9 expression and its role
seem to vary in different tumour types (Fenger et al.,
2014; Hildebrandt et al., 2010; Lu et al., 2012, 2014a,
b; Sun et al., 2013; Yu et al., 2014). Several target
genes of miR-9 have been identified including E-cad-
herin (Ma et al., 2010), NFjB1 (Bazzoni et al., 2009)
and CXCR4 (He et al., 2017).
CXCR4 is a 352 amino acid rhodopsin-like alpha
G-protein-coupled receptor that exclusively binds the
CXCR4 chemokine stromal cell-derived factor 1
(SDF-1) also known as CXCL12 (Busillo and Benovic,
2007). Knockout studies of either CXCL12 or CXCR4
in mice have shown similar phenotypic consequences,
late gestational lethality, bone marrow colonisation,
cardiac septum formation and defects in B-cell lym-
phopoiesis indicating that CXCR4 is essential for
development (Nagasawa et al., 1996; Zou et al., 1998).
Moreover, CXCR4 is important in classical chemokine
receptor response in adults as well as neutrophil matu-
ration (Machado et al., 2016). CXCR4 has been impli-
cated in tumour metastasis in several tumour models
including melanoma (Neagu et al., 2015), prostate (Lee
et al., 2014) and neuroblastoma metastasis (M€uhlethaler-
Mottet et al., 2015) and has been suggested as a bio-
marker for HNSCC with high metastatic potential
(Albert et al., 2013). Plerixafor is the only approved
drug that targets CXCR4 and CXCR7. It is used to
mobilise haematopoietic stem cells (HSCs) from the
bone marrow into the peripheral blood circulation in
the 30–40% of lymphoma and multiple myeloma
patients who do not respond to the effects of granu-
locyte colony-stimulating factor (G-CSF) alone
(Wagstaff, 2009). Currently, using plerixafor in com-
bination with conventional therapy is in clinical
trials for other cancers such as prostate and cervical
cancer (Chaudary et al., 2017; Conley-LaComb et al.,
2016) but not HNSCC. Additionally, plerixafor is
the only approved drug for selecting haematological
stem cells for autologous stem cell transplantation
(Anonymous, 2007).
We performed miRNA expression profiling of a
panel of HNSCC tumours and found that miR-9 was
significantly downregulated in a group of HNSCC
patients with known negative clinical outcome after
conventional treatment. We subsequently performed
functional studies by modulating miR-9 expression in
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a panel of HNSCC cell lines. Knockdown of miR-9 in
HNSCC cells resulted in increased proliferation, cell
cycle progression, increased invasion and enabled col-
ony formation in soft agar. By luciferase reporter
assay, we confirmed CXCR4 to be a direct target of
miR-9 in HNSCC. The knockdown of miR-9 or over-
expression of CXCR4 in HNSCC cell lines had similar
consequences on tumour cell behaviour. Importantly,
the effect of miR-9 knockdown could be abrogated by
treatment of cells with CXCR4-specific inhibitor pler-
ixafor.
This study demonstrates a clear tumour suppressor
role for miR-9 in HNSCC and suggests that the poten-
tial oncogenic effects of miR-9 knockdown in HNSCC
are mediated through targeting CXCR4. Furthermore,
we demonstrate that miR-9 may be a potential bio-
marker for response of HNSCC to the CXCR4 inhibi-
tor plerixafor.
2. Materials and methods
2.1. Cell lines and culture
The cell lines HSC3 and HSC3M3 were gifts from
Kazuya Tominaga, Department of Oral Pathology,
Osaka Dental University (Hirakata, Osaka, Japan).
The H357 cell line was a gift from Stephen Prime,
Department of Oral and Dental Science, University
of Bristol (Bristol, UK). HN5 was obtained from
Professor Barry Gusterson, Department of Pathology,
University of Glasgow, UK, and HN30 from
Andrew Yeudall, Philips Institute of Oral and Cranio-
facial Molecular Biology, Virginia Commonwealth
University, Richmond, Virginia, USA. HEK293T cells
were provided by Lucas Chan, Rayne Institute,
King’s College London, UK. MDA-MB-231 was
obtained from Joy Burchell, Breast Cancer Biology
Group, King’s College London, UK, to act as a posi-
tive control for the invasion assay. Five head and
neck cancer cell lines were profiled for expression of
miR-9. Two cell lines with high (HN30 and H357)
and two cell lines with low (HSC3 and HN5) miR-9
expression were selected for further investigation. Cell
lines were authenticated by STR profiling. STR pro-
files were obtained using the Promega Powerplex 16
assay according to the manufacturer’s procedure.
STR profiles were compared to published profiles
(web.expasy.org/cellosaurus/). For H357, there is no
published STR profile but a search of the ATCC
database did not find significant homology with other
cell lines.
All cell lines except H357 were cultured in DMEM
supplemented with 10% FBS, 50 lgmL1 streptomycin,
100 lgmL1 penicillin and 1 mM sodium pyruvate.
H357 cells were cultured in DMEM-F12 supplemented
with 10% FBS, 4 mM L-glutamine, 69 nM hydrocorti-
sone, 5 lgmL1 streptomycin, 5 lgmL1 penicillin
and 1 mM sodium pyruvate. The CXCR4-specific
ligand CXCL12 (Bio-Techne) was supplemented to
appropriate cell media at a final concentration of
100 ngmL1 whereas the CXCR4-specific inhibitor,
plerixafor (Cambridge Bioscience, Cambridge, UK),
was supplemented to appropriate cell media at a final
concentration of 500 ngmL1.
2.2. Plasmids and transfection
MiR-9 was PCR-amplified from HeLa genomic DNA as
a 977-bp fragment using the following primers:
GATGCGCCCTCGATCTTC and CTGTGGGAAAG-
TGTTCAC. The PCR products were TA cloned into
pCR2.1 (Invitrogen, Carlsbad, CA, USA), and the
sequence was verified with M13 forward and reverse pri-
mers and two internal primers F:CAAGTTGACC-
AGTGCCGTTC and R:CTCGGTACCCCACGA-
AGTG. A scrambled sequence was used as a control for
the miR-9 constructs. Calcium phosphate precipitation
was used to transfect the HEK293T to generate miR-9
knockdown and overexpression retrovirus as previously
described (Suh et al., 2015). CXCR4 overexpression/
knockdown constructs were gifts from Gilbert
Fruhwirth, Faculty of Life Sciences and Medicine King’s
College London. HA-CXCR4 overexpression retrovirus
and shRNA CXCR4 knockdown lentivirus were gener-
ated in HEK293T after calcium phosphate transfection
as previously described (Suh et al., 2015). At 24, 36 and
48 h after transfection, viral supernatants were harvested
and filtered through a 0.45-lm filter and supplemented
with 5 lgmL1 polybrene. Cells were infected with the
virus overnight, and the infected cells were selected based
on their newly acquired antibiotic resistance.
2.3. Luciferase gene reporter assay
5 9 103 cells were seeded per well on a 96-well plate
overnight, and the cells were infected with MISSION
CXCR4 30UTR Lenti GoClone (Sigma, St. Louis,
MO, USA) for 48 h. The activity of the luciferase was
determined using the Dual-Glo Luciferase Assay Sys-
tem (Promega, Madison, WI, USA) according to the
manufacturer’s instructions. Firefly bioluminescence
was used as experimental read-out with Renilla biolu-
minescence as an internal control. Samples were mea-
sured on a Veritas Luminometer (Turner Biosystems,
Sunnyvale, CA, USA). Untransfected cells served as
negative control.
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2.4. RNA extraction and qRT–PCR
Total RNA was isolated from 2 9 106 cells using Trizol
(Invitrogen). cDNA was generated from 10 ng of RNA
with miR-9 and RNU6B primers (Applied Biosystems,
Foster City, CA, USA) and the TaqMan miRNA Reverse
Transcription Kit (Applied Biosystems). Whereas for
CXCR4 expression, cDNA was synthesised from 1.5 lg
RNA with CXCR4 (Integrated DNA Technologies, Sko-
kie, IL, USA) and YWHAZ primers (Sigma) and the
SuperScript III Reverse Transcriptase kit (Thermo-
Fisher). Quantitative PCR was performed on the Corbett
Rotor-Gene 6000 with TaqMan Universal Mastermix-No
UNG (Applied Biosystem) for miR-9 and 5x EvaGreen
qPCR mix for CXCR4 (Solis Biodyne, Tallinn, Estonia).
Delta-Ct was calculated after normalising to RNU6B for
miR-9 and YWHAZ for CXCR4. miR-9 primers were
purchased from Applied Biosystems, and CXCR4 primers
were designed on primer 3 and purchased from Integrated
DNA Technologies (CXCR4 primer sequence, forward:
ACGCCACCAACAGTCAGAG and reverse: AGT
CGGGAATAGTCAGCAGGA30). qRT–PCR analysis
was carried out on three independent RNA samples.
2.5. Proliferation assay
Stably transfected cells were seeded in triplicate in 6-
well plates (1.2 9 104 cells per well). Cells were har-
vested and counted in triplicate over the next 5 days.
Proliferation was also assessed using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) cell viability assay as previously described (Suh
et al., 2015). Optical density was measured at a wave-
length of 595 nm on a Tecan Infinite F50.
2.6. Cell cycle assay
The cell lines were synchronised using two 18-h thymi-
dine (2 mM) blocks with an 8-h release. 1 9 106 cells
were harvested and centrifuged for 5 min at 1000 g.
The cell pellets were fixed in 500 lL 1x PBS and
4.5 mL cold 70% ethanol overnight at 4 °C. After
24 h, the cells were centrifuged for 10 min at 1000 g,
and the cells were washed once with 1x PBS, treated
with 300 lL of RNase A/PBS solution (1 mgmL1)
and stained with propidium iodide (50 lgmL1,
Sigma) solution at 37 °C for 30 min. The DNA his-
tograms were generated with a Becton Dickinson Bio-
science (BD) Aria flow cytometer.
2.7. Scratch assay
Confluent cells were serum starved for 24 h, before a
scratch was introduced using a p200 pipette tip.
Floating cells were removed by washing twice with
PBS before the reintroduction of media with 10%
FBS. Images were taken at 0 and 8 h. The area
between the scratch was imaged and analysed using
ImageJ and the percentage of the scratch area closed
between the time points calculated.
2.8. Soft agar colony-forming assay
Sterile agarose solution of 1% and 0.6% in sterile
water was mixed with the same volume of 2 9
DMEM or DMEM F-12 with 20% FBS and used as
bottom and top layers, respectively. 5x103 cells in
100 ll of appropriate culture medium were added to
the top layer for 21 days. Colonies were fixed with 4%
paraformaldehyde and stained with 0.1 mL of Crystal
violet (0.5 mgmL1 in PBS). Images were acquired
with x20 objective on an Olympus BX61 microscope.
2.9. Anoikis resistance sphere assay
Cell was disaggregated into a single-cell suspension
and plated at 500 cellscm2 into polyhema [1.2% poly
(2-hydroxyethylmethacrylate)/95% ethanol] coated 6-
well plates for 5 days. Spherical colonies >60 lm were
counted over subsequent generations to discount
aggregates. Normalised percentage sphere-forming effi-
ciency was calculated as number of spheres formed
divided by the number of cells seeded and then nor-
malised against the control.
2.10. Matrigel transwell invasion assay
Cell was seeded at 4x105/mL in serum-free media in
12-well transwell 300 lgmL1 Matrigel-coated inserts
for 24 h (BD Biosciences, San Jose, CA, USA). Che-
moattractant (medium containing 5% FBS and med-
ium containing 5% FBS + CXCL12) was added to the
bottom chamber of each transwell. The noninvading
cells in the upper chamber were removed, and the
invading cells were fixed in 100% methanol, stained
with 1% toluidine blue/borax solution and scored.
Five representative images from each membrane were
counted and invasion was expressed as the percentage
invaded cell through the Matrigel membrane relative
to the cells seeded.
2.11. 3D invasion assay
The assay was performed as previously described in
Berens et al. (2015). A cell suspension of 5 x 104
was generated and hanging drop cultures made by
placing 20 lL drops of cell suspension on to the lid
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of a 10-cm dish using a multichannel pipette (five
rows of eight drops making 40 drops). Five microli-
tres of sterile PBS was added to the dish to prevent
the hanging drops from evaporation. The lid is
inverted and incubated at 37 °C for 72 h for spher-
oid formation.
After 72 h, an artificial ECM mixture was created
consisting of 100 lL of growth factor-reduced Matri-
gel (BD Biosciences) mixed with 100 lL of type I col-
lagen per well and maintained on ice. The spheroids
were collected and transferred into a 1.5-mL microcen-
trifuge tube, and the spheroids were allowed to settle
for 10 min. The spheroids were aspirate from the bot-
tom 40 lL and added to 200 lL of the ECM mixture.
Forty microlitres of the spheroid/ECM mixture was
added to the centre of a 24-well plate and placed in a
37 °C incubator for 30 min to polymerise the ECM
mixture. After 30 min, 1 mL of 37 °C cell culture
media was added to each well slowly to prevent dis-
lodging.
2.12. Statistical analysis
Student’s two-tailed t-test was performed for assessing
differences between two independent groups. When mea-
suring several independent factors between several groups,
two-way ANOVA was used. GRAPHPAD PRISM 5.03 was
used for statistical analyses (La Jolla, CA, USA).
3. Results
3.1. miR-9 affects cellular proliferation, cell cycle,
colony formation and invasion in HNSCC
The expression of miR-9 was investigated in five head
and neck cancer cell lines (Fig. 1A), and based on
miR-9 expression levels, HSC3, HN5, HN30 and H357
were selected for further functional characterisations.
In HSC3 and HN5, both of which have relatively low
endogenous miR-9 expression, miR-9 was overex-
pressed, and in H357 and HN30 with relatively high
endogenous miR-9 expression levels, it was knocked
down. Analysis by qRT-PCR confirmed miR-9 overex-
pression in HSC3 and HN5 by 800 (P < 0.05, Fig. 1B)
and 25-fold (P < 0.001, Fig. 1C), respectively, com-
pared to vector controls. However, in H357 and HN30
cells, miR-9 knockdown resulted in approximately
40% (P < 0.001, Fig. 1D) and 22% (P < 0.05,
Fig. 1E) decrease, respectively, compared to scrambled
controls.
Cellular proliferation experiments demonstrated
suppression of cellular growth induced by miR-9
overexpression; HSC3 miR-9-overexpressing cells
showed a significant decrease in proliferation rate
with 33% fewer cells compared to vector control on
day five (P < 0.01, Fig. 2A). MiR-9 knockdown in
H357 increased proliferation rate over five days
(P < 0.01, Fig. 2B), with a 1.42-fold increase on day
4 and 1.44-fold on day 5 in the miR-9 knockdown
compared to scrambled control. Immunoblotting for
apoptotic markers, PARP and caspase 3, did not
show differences between the miR-9-modulated cell
lines (Fig. S1), indicating that apoptosis was not the
cause of miR-9-mediated reduced cellular prolifera-
tion. However, cell cycle analysis demonstrated dif-
ferences in the cell cycle distribution with miR-9
knockdown H357 showing decrease in G2/M phase
of the cell cycle compared to scrambled control
(P < 0.01, Fig. S2b) with 10.0% of the scrambled
control cells in G2/M compared to 3.7% in miR-9
knockdown cells.
Overexpression of miR-9 in HSC3 cells resulted in a
substantial ~88% reduction in colony formation in soft
agar compared to vector control (P < 0.001, Fig. 2C).
In contrast, miR-9 knockdown clearly resulted in the
ability to form colonies in soft agar compared with no
colonies formed in the scrambled control (P < 0.001,
Fig. 2D). Furthermore, miR-9 overexpression resulted
in a marked decrease in cellular invasion compared to
control cells, the highly invasive breast cancer cell line
MDA-MB-231 was used as a positive control
(P < 0.0001, Fig. 2E). Approximately 10% of miR-9-
overexpressing HSC3 cells invaded through the
membrane compared to 40% in vector controls. By
contrast, invasion increased significantly by miR-9
knockdown (P < 0.0001, Fig. 2F) in H357 cells with
approximately 60% of miR-9 knockdown cells invad-
ing compared to ~20% in scrambled control cells.
Similar effects of miR-9 modulation on proliferation,
cell cycle and colony formation were observed in other
HNSCC cell lines (HN5 and HN30, Fig. S3).
3.2. miR-9 directly regulates CXCR4 expression in
HNSCC
To identify target gene/s of miR-9, a database (miR-
anda and TargetScan) search was conducted. Both
algorithms indicated that miR-9 could target evolu-
tionarily conserved sequences in CXCR4 mRNA
(Fig. 3A,B). Consequently, CXCR4 expression was
analysed in HSC3 and H357 parental cell lines, scram-
bled controls and miR-9 overexpression/knockdown
cell lines by qRT–PCR.
Clear reverse correlation between endogenous level
of miR-9 and CXCR4 expression was detected with
approximately 40-fold increase in CXCR4 expression
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between the low miR-9 expressing HSC3 and high
miR-9 expressing H357 cell lines (P < 0.0001,
Fig. 3C). Knockdown of miR-9 had no significant
effect on CXCR4 expression in HSC3 cells which
have low endogenous miR-9 (Fig. 3D), whereas miR-
9 knockdown in H357 resulted in over eightfold
increase in CXCR4 expression (P < 0.001, Fig. 3E).
Notably, miR-9 overexpression in HSC3 resulted in
almost 90% decrease in CXCR4 expression
(P < 0.0001, Fig. 3F) and miR-9 overexpression in
H357 resulted in an approximately 60% decrease in
CXCR4 level compared to controls (P < 0.001,
Fig. 3G).
These data show a clear link between miR-9 and
CXCR4 expression. To confirm whether miR-9 directly
regulates CXCR4 expression, a luciferase reporter con-
struct containing the 30-UTR of the CXCR4 gene was
introduced into miR-9-modulated cells. An almost 90%
reduction in relative luciferase activity was detected in
miR-9-overexpressing HSC3 cells compared to vector
control (P < 0.0001, Fig. 3H) and a 1.35-fold increase
in relative luciferase activity in H357 miR-9 knockdown
cells compared to scrambled control (P < 0.0001,
Fig. 3I). These data confirm that CXCR4 is a direct
target of miR-9 regulation in HNSCC cell lines.
3.3. miR-9 regulation of CXCR4 affects cellular
proliferation, cell cycle, colony formation and
invasion
Given the link between miR-9 and CXCR4, expression
of CXCR4 was modulated in HSC3 and H357 cell
lines. CXCR4 knockdown in HSC3 cells resulted in
almost 25% reduction in CXCR4 expression
(P < 0.05, Fig. 4A) whereas CXCR4 overexpression in
H357 cells showed 12-fold increase in CXCR4 expres-
sion (P < 0.001, Fig. 4B). Despite partial CXCR4
knockdown in HSC3, a significant decrease in prolifer-
ation rate was observed, with about 26.1% and 29.9%
decrease on days 4 and 5, respectively (P < 0.01,
Fig. 4C), compared to control. Whereas in H357,
CXCR4 overexpression increased proliferation (P < 0.01,
Fig. 4D), with 1.25-fold and 1.4-fold more cells on
days 4 and 5, respectively, in the CXCR4 overexpres-
sion cells compared to vector control. This result
mirrors the effects on cellular growth observed with
miR-9 modulation.
Additionally, CXCR4 modulation had correspond-
ing effects on cell cycle distribution: CXCR4 knock-
down in HSC3 cells showed an increase in G2/M
phase from 7.8% to 13.2% (P < 0.01, Fig. S4a), whilst
Fig. 1. miR-9 expression in a panel of HNSCC cell lines and the modulated cell lines. (A) Relative expression of miR-9 in six different
HNSCC cell lines using qRT–PCR normalised against HSC3. (B) HSC3 and (C) HN5 were stably transduced with miR-9 overexpression
vectors, and levels were measured by qRT–PCR (D) H357 and (E) HN30 were stably transduced with miR-9 knockdown vectors, and the
efficiency of knockdown was measured by qRT–PCR. Data represent mean  SEM for three independent (n = 3) experiments. Asterisks (*)
show statistical significance as follows: *P < 0.05, **P < 0.01, ***P < 0.001.
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Fig. 2. Effect of miR-9 modulation on proliferation, cell cycle, colony formation and invasion. HSC3 and H357 cell lines were stably
transfected using miR-9 knockdown and overexpression vectors, respectively, and expression was measured by qRT–PCR. Cell proliferation
of (A) miR-9 overexpression in HSC3 and (B) miR-9 knockdown in H357 cells was assessed by generating growth curves over 5 days. The
ability of (C) HSC3 miR-9 overexpression and (D) H357 miR-9 knockdown cells to form colonies was tested using the soft agar assay.
Invasive capacity of (E) HSC3 miR-9 overexpression and (F) H357 miR-9 knockdown was assessed using the Transwell Matrigel invasion
assay. Representative images were taken at 109 magnification. Data represent mean number of invaded cells through the Matrigel
membrane relative to migration through the control membrane. Images are representative of cells fixed and stained on the invasion
membrane at 49 magnification. Scale bars = 100 lm Data represent mean  SEM for three independent (n = 3) experiments. Asterisks (*)
show statistical significance as follows: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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CXCR4 overexpression in H357 resulted in a statisti-
cally significant decrease in G2/M phase, from ~12%
to ~5% (P < 0.001, Fig. S4b).
Similar to miR-9, CXCR4 was found to strongly
affect the colony-forming ability and invasive capacity
of the HNSCC cell lines. CXCR4 HSC3 knockdown
cells showed a 50% decrease in the number of colonies
formed in soft agar compared to the scrambled control
(P < 0.05, Fig. 4E). Interestingly, CXCR4 overexpres-
sion in H357, which generally do not grow in soft
agar, conferred the colony formation ability similar to
the results observed with miR-9 knockdown
(P < 0.0001, Fig. 4F). CXCR4 knockdown in HSC3
cells also reduced invasion capacity in these cells com-
pared to scrambled control cells (P < 0.05, Fig. 4G)
whilst its overexpression induced almost twofold
Fig. 3. miR-9 directly regulates CXCR4 expression. Online computer algorithm (A) TargetScan and (B) miRanda predicting CXCR4 as a miR-9
target. qRT–PCR was performed to compare CXCR4 expression in (C) HSC3 vs H357, (D) HSC3 miR-9 knockdown, (E) H357 miR-9
knockdown versus the scrambled controls, whereas (F) HSC3 miR-9 overexpression and (G) H357 miR-9 overexpression were compared to
the vector control. Luciferase assays confirming miR-9 interaction with the 30UTR of CXCR4 were performed for (H) miR-9 knockdown and
(I) miR-9 overexpression. Data represent mean SEM for three independent (n = 3) experiments. Asterisks (*) show statistical significance
as follows: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Fig. 4. CXCR4 modulations affect cellular proliferation, cell cycle, colony formation and invasion. HSC3 and H357 were stably transfected
using (A) CXCR4 knockdown and (B) overexpression vectors and analysed using qRT–PCR. Cell proliferation of (C) CXCR4 knockdown and
(D) overexpression H357 cells was assessed by generating growth curves over 5 days. The ability of the (E) CXCR4 knockdown and (F)
overexpression cells to form colonies was tested using the soft agar assay. Representative images were taken at 109 magnification.
Invasive capacity of (G) CXCR4 knockdown and (H) overexpression cells was assessed using the Transwell Matrigel invasion assay.
Representative images were taken at 109 magnification. Data represent mean number of invaded cells through the Matrigel membrane
relative to migration through the control membrane. Images are representative of cells fixed and stained on the invasion membrane at 49
magnification. Scale bars = 100 lm Data represent mean  SEM for three independent (n = 3) experiments. Asterisks (*) show statistical
significance as follows: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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increase in invasion rising from 20% in controls to
40% in overexpressing cells (P < 0.01, Fig. 4H). The
effects of CXCR4 modulation on regulating prolifera-
tion, cell cycle and colony formation and invasion pro-
vide strong evidence for miR-9 tumour-suppressive
effects being mediated via the inhibition of CXCR4.
3.4. The CXCR4 ligand CXCL12 stimulates the
oncogenic effects of miR-9 knockdown
To investigate the relationship between miR-9 and
CXCR4, cellular proliferation, migration and colony
formation assays were performed in the presence of
CXCR4-specific ligand CXCL12.
As demonstrated above, CXCR4 overexpression or
miR-9 knockdown by itself increased proliferation of
H357 cells. Whilst CXCL12 had no effect on cellular
proliferation of the vector control cells, there was an
approximately 2.33-fold (P < 0.0001) and 1.6-fold
(P < 0.001) increase in proliferation on days 3 and 4,
respectively, between unstimulated and stimulated
CXCR4-overexpressing cells treated with CXCL12
(Fig. 5A,B). Interestingly, miR-9 knockdown cells had
a similar response; CXCL12 had no effect on the
scrambled control cells but caused an approximately
2.2-fold (P < 0.05) increase in proliferation on day 3
between stimulated and unstimulated miR-9 knock-
down cells (Fig. 5C,D).
Vector control cells showed no difference in migra-
tion after CXCL12 stimulation; however, CXCL12
stimulation induced a 2.5-fold increase in migration in
CXCR4-overexpressing cells (P < 0.05, Fig. 5E). Addi-
tionally, CXCL12 stimulation of CXCR4-overexpres-
sing cells resulted in an approximately 1.5-fold
increase in anoikis-resistant spheroid colonies in low
adherent conditions compared to treated and untreated
controls (P < 0.01, Fig. 5F).
Interestingly, wound healing assay showed that
although miR-9 knockdown by itself did not result in
a change in migration of H357 cells compared to
scrambled control cells, when stimulated with CXCL12,
knockdown of miR-9 induced a 1.5-fold increase in gap
closure as compared with scrambled control cells
(Fig. 5G). Additionally, CXCL12 stimulation of scram-
bled control cells had no effect on colony formation
whereas miR-9 knockdown cells had a significant
increase (over 1.2-fold) in anoikis-resistant spheroid
colonies after CXCL12 stimulation (P < 0.01, Fig. 5H).
Together, these results indicate that miR-9 knockdown
similar to CXCR4 overexpression makes cells respon-
sive to CXCL12 and strongly suggest that miR-9
tumour-suppressive effects are mediated via CXCR4
pathway.
3.5. CXCR4-specific inhibitor plerixafor mimics
the tumour-suppressive role of miR-9
To further investigate the association between miR-9
and CXCR4 activities in HNSCC, the CXCR4-specific
inhibitor plerixafor was used. Treatment of miR-9
knockdown (Fig. S5a) and CXCR4-overexpressing
(Fig. S5b) cells with plerixafor showed a dose-depen-
dent decrease in cell viability in both groups.
The effect of plerixafor treatment on proliferation
was investigated on CXCR4-overexpressing and vec-
tor control cells (Fig. 6A,B). Plerixafor treatment of
vector control cells had no effect on proliferation
(Fig. 6A), whereas CXCR4-overexpressing cells had a
near-complete loss in proliferation over five days
(P < 0.01, Fig. 6B). This effect was also observed in
miR-9 knockdown cells, with plerixafor treatment
drastically reducing proliferation in only the miR-9
knockdown cells (P < 0.001, Fig. 6C,D). Interest-
ingly, plerixafor inhibited the CXCL12 stimulated
increase in proliferation in miR-9 knockdown cells
(Fig. S6).
Moreover, the inhibitory effect of plerixafor, specifi-
cally on CXCR4-overexpressing and miR-9 knock-
down cells, was seen by changes in cell cycle profile:
treatment of miR-9 knockdown cells significantly
increased G2/M progression, rising from 3.9% in
untreated cells to 14.7% in treated cells (P < 0.0001,
Fig. S7a). Treatment of CXCR4-overexpressing cells
also resulted in a marked increase in G2/M phase
compared to untreated (5.5% to 13.8%, untreated and
treated; P < 0.0001, Fig. S7b).
Plerixafor treatment also affected migration with
CXCR4-overexpressing cells showing 50% decrease in
migration with plerixafor treatment when compared to
untreated and treated control cells after plerixafor
treatment (P < 0.0001, Fig. 6E) and plerixafor treat-
ment of miR-9 knockdown cells resulted in 30%
decrease in migration compared to untreated and trea-
ted controls (Fig. 6F).
Additionally, CXCR4 overexpression and miR-9
knockdown in H357 increased the ability of these
cells to form spheroid colonies in low adherent con-
ditions and plerixafor treatment was sufficient to sig-
nificantly block this ability. Plerixafor treatment of
CXCR4-overexpressing cells decreased spheroid for-
mation by approximately 71.4% (p < 0.01, Fig. 6G)
whilst treatment of miR-9 knockdown cells decreased
spheroid formation by about 62.5% (p < 0.0001,
Fig. 6H). Collectively, these data further support
miR-9 regulating CXCR4 expression in HNSCC and
suggests miR-9 as a potential biomarker for plerix-
afor response.
2032 Molecular Oncology 12 (2018) 2023–2041 ª 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
MiR-9 predictive of plerixafor response in HNSCC H. M. Hersi et al.
Fig. 5. The CXCR4 ligand CXCL12 augments the oncogenic effects of miR-9 knockdown. Cell proliferation in the presence of CXCL12 was
assessed by MTT assay over 5 days in (A) CXCR4-overexpressing and (B) vector control H357 cells. The effect of CXCL12 on cell
proliferation was also assessed by MTT assay in (C) miR-9 knockdown and (D) scrambled control H357 cells over 5 days. (E) The effect that
CXCL12 stimulation of CXCR4 had on migration was examined by scratch assay using CXCR4-overexpressing H357 cells. (F) Using sphere
formation assay, the effect of CXCL12 on colony formation was investigated using CXCR4-overexpressing H357 cells. (G) Migration of miR-
9 knockdown cells stimulated by CXCL12 was studied using scratch assay. (H) Sphere-forming capacity of miR-9 knockdown cells was
similarly measured in the presence of CXCL12. Data represent mean SEM for three independent (n = 3) experiments. Asterisks (*) show
statistical significance as follows: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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Fig. 6. Plerixafor treatment mimics the tumour-suppressive effect of miR-9 via CXCR4 inhibition. Cell proliferation of (A) vector control and
(B) CXCR4 overexpressing H357 cells was assessed by MTT assay over 5 days. Proliferation of (C) miR-9 knockdown and (D) scrambled
control H357 cells was also assessed by MTT assay over 5 days. (E) The effect of plerixafor on migration was examined by scratch assay
using CXCR4-overexpressing H357 cells. (F) Using sphere formation assay, the effect on colony formation was investigated using CXCR4-
overexpressing H357 cells. (G) Migration of miR-9 knockdown cells was studied using scratch assay. (H) Sphere-forming capacity of miR-9
knockdown cells was similarly measured in the presence of plerixafor. Data represent mean SEM for three independent (n = 3)
experiments. Asterisks (*) show statistical significance as follows: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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3.6. miR-9 and CXCR4 regulate spheroid
formation and invasion in 3D physiological
conditions
Having shown acquisition of anchorage-independent
growth as well as the increased migratory and invasive
capacity of HNSCC cells with miR-9 knockdown and
CXCR4-overexpressing cells in 2D culture, we then
went on to investigate these phenotypes in 3D anchor-
age-independent condition.
Both miR-9 knockdown and CXCR4-overexpressing
cells were able to form 3D spheroids in hanging drop
conditions as described in the Materials and Methods
section, whereas the controls cells were unable to form
any spheres (data not shown). Importantly, miR-9
knockdown and CXCR4-overexpressing spheroids
were only able to invade into the artificial extracellular
matrix when treated with CXCL12 compared to nor-
mal media and media containing the inhibitor plerix-
afor. Spheroid invasion was assessed based on the
longest invasive distance from the centre of the spher-
oid and the total area changed in the area invaded by
the spheroid. MiR-9 knockdown spheroids invaded
more uniformly into a greater area (Fig. 7A,
P < 0.0001) as opposed to travelling a greater distance
(Fig. 7B, P < 0.05) over 48 h. The opposite was true
for CXCR4-overexpressing spheroids, which had a
modest increase in total area invaded (Fig. 7C,
p < 0.05) but travelled a significantly larger distance
(Fig. 7D, P < 0.001) over a 48-h period.
4. Discussion
Treatment options for HNSCC have remained rela-
tively unchanged over the past 30 years and these can-
cers still have high relapse and mortality rates
(Mehanna and Ang, 2012). Increasing evidence indi-
cates the importance of miRNA in different aspects of
cancer development and progression (Lu et al., 2005).
Previous data from our laboratory showed that in a
group of head and neck cancer patients with good and
bad clinical outcomes, miR-9 was significantly down-
regulated in the patients with poor clinical outcome
(Suh et al., 2015). Here, we used functional studies
and demonstrated that knockdown of miR-9 in
HNSCC cell lines increased proliferation, cell cycle
progression, colony formation and invasion. We iden-
tified CXCR4 as the important target gene of miR-9
with CXCR4-overexpressing cells having the reciprocal
effect to miR-9 knockdown. The direct link of miR-9
and CXCR4 was confirmed by CXCR4 inhibitor pler-
ixafor which reduced the oncogenic phenotype in both
CXCR4-overexpressing and miR-9 knockdown cells.
Collectively, these data indicated that miR-9 is a
tumour suppressor and implies CXCR4 as its potential
oncogene target in HNSCC.
In recent years, miR-9 has emerged as an impor-
tant miRNA in cancers and its role seems to vary in
different tumour types (Fenger et al., 2014; Hilde-
brandt et al., 2010; Lu et al., 2012, 2014a,b; Sun
et al., 2013; Yu et al., 2014). In HNSCC, miR-9 has
been shown to be downregulated (Lujambio et al.,
2008) with hypermethylation of miR-9 loci being a
frequent occurrence in HNSCC (Minor et al., 2012).
The restoration of miR-9 expression via demethyla-
tion of miR-9 promotor sites inhibited viability of
HNSCC cells (Minor et al., 2012). Furthermore,
lower miR-9 expression was observed in colon cancer
and malignant melanoma tissues when compared to
their respective normal tissue and this corresponded
with increased cellular proliferation and decreased
apoptosis (Bu et al., 2017; Cekaite et al., 2012). This
reduction in miR-9 is also observed in malignant mel-
anoma cell lines and the ectopic expression of miR-9
resulted in significant suppression of the proliferative
ability of the malignant melanoma cell lines (Bu
et al., 2017).
We found that miR-9 knockdown promoted colony
formation (Fig. 2C,D). To our knowledge, this is the
first evidence of miR-9 knockdown in HNSCC cells
inducing anoikis-resistant growth. Intratumoral injec-
tion of miR-9 into a nasopharyngeal carcinoma cell
line grafted to the mouse liver resulted in fewer micro-
scopic and macroscopic metastases (Lu et al., 2014a,
b). Subsequent work from the same group considered
the role of miR-9 in regulating metastasis. They identi-
fied that miR-9 directly regulated E-cadherin expres-
sion (Ma et al., 2010). E-cadherin is a well-established
protein marker of EMT, mediating cell adhesion and
loss of it promotes tumour metastasis (reviewed (Hu
et al., 2016)). Loss of the epithelial marker E-cadherin
and gaining a mesenchymal marker such as vimentin
are characteristic of a metastatic phenotype (White
et al., 2013). Intriguingly, various studies in prostate
(Dhingra et al., 2017), breast (Ma et al., 2010) and
ovarian cancer (Zhou et al., 2017) have shown that
overexpression of miR-9 correlated with decreased
E-cadherin expression. However, in HNSCC, miR-9
expression has been found to be downregulated
(Lujambio et al., 2008; Minor et al., 2012). Therefore,
it is unlikely that the tumour suppressor effects of
miR-9 in HNSCC are through E-cadherin but poten-
tially through another of its oncogenic targets such as
CXCR4 expression (Fenger et al., 2014; Hildebrandt
et al., 2010; Lu et al., 2012, 2014a,b; Sun et al., 2013;
Yu et al., 2014).
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CXCR4 expression levels are generally low or absent
in most healthy tissues; however, in cancer, CXCR4
was found to be overexpressed in a variety of cancers
over 23 types of cancer (Sun et al., 2010). Overexpres-
sion of CXCR4 has been implicated in tumour metas-
tasis and has been found to metastasise to tissues with
a high concentration of CXCL12, such as lungs, liver
and bone marrow (Balkwill, 2004). Interestingly,
immunohistochemistry on 79 oesophageal squamous
cell carcinoma tissue samples found that the prolifera-
tion index was higher in patients samples with higher
expression of CXCR4 or CXCL12 (Uchi et al., 2016).
This effect on cell proliferation was also observed
in vitro where inhibition of CXCR4 suppressed
Fig. 7. miR-9 and CXCR4 regulate invasion under anchorage-independent conditions. Invasion of miR-9 knockdown cells was quantitated
using IMAGEJ software. Invasion of miR-9 knockdown cells was calculated by measuring the (A) total area invaded by the spheroid and (B)
the longest invasive distance from the spheroid. Invasion of CXCR4-overexpressing cell was also investigated by (C) total area invaded and
(D) longest invasive distance. Data represent mean SEM for three independent (n = 3) experiments. Scale bars = 100 lm Asterisks (*)
show statistical significance as follows: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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proliferation of synovial sarcoma cell lines (Kimura
et al., 2016). Moreover, CXCR4 signalling has a role
in cell cycle regulation. In glioblastoma, CXCL12
stimulation of CXCR4 increased cell cycle progression
and EMT through expression of survivin (Liao et al.,
2016). In mouse models, myeloid bone marrow-derived
cells gained promigratory ability when CXCR4 was
stimulated by CXCL12 (Peled and Tavor, 2013).
Intriguingly, we found that CXCR4 overexpression in
H357 resulted in increased anoikis resistance growth
(Fig. 4F). Ligand activation of CXCR4 receptor
increased anoikis resistance via the upregulation of
Bcl-xL and downregulation of BMF (Kochetkova
et al., 2009). Moreover, CXCR4 overexpression has
previously been linked to increased colony formation
in other cancer types (Liang et al., 2015). Silencing
CXCR4 expression in breast cancer cell lines signifi-
cantly decreased colony formation and overexpression
of CXCR4 had the opposite effect (Liang et al., 2015).
Additionally, higher CXCR4 expression increased the
invasive capacity of the miR-9 knockdown and
CXCR4 overexpression cells both in 2D (Figs 2F and
4H respectively) and, interestingly, in 3D settings
(Fig. 7). CXCR4 has been heavily linked to an increas-
ingly invasive phenotype in a variety of cancers types;
however, many of the studies have looked at CXCR4
invasion in only a 2D setting (Guo et al., 2015; Jeong
et al., 2014; Niu et al., 2015; Xu et al., 2015; Ying
et al., 2015). To our knowledge, this is the first experi-
mental evidence of miR-9 knockdown inducing an
invasive phenotype via CXCR4 in 3D culture. There is
one study that shows CXCR4-induced invasion in a
3D setting, increased invasion of glioblastoma spher-
oids which could be abrogated through proteolytic
cleavage of CXCL12 by cathepsin K (Hira et al.,
2017).
We found that the CXCR4 inhibitor plerixafor
reversed the effects of CXCR4 overexpression but
most importantly also affected growth and invasive-
ness of miR-9 knockdown cells in the HNSCC cell
lines (Fig. 6). To our knowledge, this is the first evi-
dence of plerixafor affecting miR-9-mediated cellular
functions. Usage of plerixafor has shown dramatic
reduction in carcinogenic phenotype induced by
CXCR4 in various in vitro cancer studies in solid
tumours such as prostate and cervical cancers (Chaud-
ary et al., 2017; Conley-LaComb et al., 2016), as well
as lymphomas (Reinholdt et al., 2016). Plerixafor is
already approved for the mobilisation of hematopoi-
etic stem cells in lymphoma and multiple myeloma
patients (Wagstaff, 2009). Moreover, inhibition of
CXCR4 via plerixafor is in clinical trials for use with
advanced pancreatic, ovarian and colorectal cancers
(CAM-PLEX NCT02179970, 2014) but not in
HNSCC. Collectively, this raises the possibility of
using plerixafor in combination with standard
chemoradiation-therapy for the treatment of head and
neck cancers.
5. Conclusion
In conclusion, the data presented here suggest that
miR-9 expression has a significant tumour suppressor
role in HNSCC cells, potentially through regulation of
cell cycle progression. Moreover, miR-9 knockdown
was shown to confer anoikis-resistant colony forma-
tion capability in soft agar as well as increased inva-
sion, and CXCR4 was identified as oncogenic target of
miR-9 in HNSCC. The ability of plerixafor to reverse
the effects of the downregulation of miR-9 on cellular
proliferation, cell cycle progression, migration and col-
ony formation indicates that miR-9 might serve as a
potential biomarker for the efficacy of plerixafor treat-
ment.
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Fig. S4. CXCR4 modulation in HNSCC cells affects
cell cycle.
Fig. S5. Plerixafor titration on CXCR4 overexpressing
and miR-9 knockdown cells.
Fig. S6. Plerixafor blocks CXCL12 induced increase in
proliferation in miR-9 knockdown cells.
Fig. S7. Effect of plerixafor on cell cycle profile.
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